샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793703

세계의 주기성 발열 증후군 시장

Periodic Fever Syndrome
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 390 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

주기성 발열 증후군 세계 시장은 2030년까지 7억 4,560만 달러에 달할 전망

2024년에 6억 1,880만 달러로 추정되는 주기성 발열 증후군 세계 시장은 2030년에는 7억 4,560만 달러에 달하고, 분석 기간 2024-2030년 CAGR은 3.2%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 고면역글로불린혈증 D 증후군은 CAGR 4.0%를 기록하며 분석 기간 종료시에는 3억 4,650만 달러에 달할 것으로 예측됩니다. 가족성 지중해열 증후군 부문의 성장률은 분석 기간 동안 CAGR 1.7%로 추정됩니다.

미국 시장은 추정 1억 6,860만 달러, 중국은 CAGR 6.1%로 성장 예측

미국의 주기성 발열 증후군 시장은 2024년에 1억 6,860만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 1억 4,810만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.2%와 2.4%로 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

세계의 주기성 발열 증후군 시장 - 주요 동향과 촉진요인 정리

주기성 발열 증후군의 특징과 오진되기 쉬운 이유는?

주기성 발열 증후군은 감염을 동반하지 않는 발열과 전신 염증의 재발을 특징으로 하는 희귀한 자가 염증성 질환군입니다. PFAPA(주기적 발열, 아프타성 구내염, 인두염, 선염), 가족성 지중해열(FMF), TRAPS(TNF 수용체 관련 주기적 증후군) 등의 증후군은 일반적으로 소아기에 발병하며, 자연 면역 체계를 조절하는 유전자의 돌연변이와 관련되어 있습니다.

감염성 질환이나 자가면역질환과 증상이 중복되어 오진되는 경우가 많습니다. 인식이 높아짐에 따라 보다 정확한 임상적 인식과 유전자 검사를 통해 임상의들은 재발성 발열의 원인을 감염, 자가면역질환, 자가염증성 질환과 구별할 수 있게 되었습니다. 이 증후군은 드물지만 삶의 질, 학업, 간병인의 부담에 심각한 영향을 미치기 때문에 조기 진단과 장기적인 치료 계획이 필요합니다.

유전학과 면역학의 발전으로 진단과 치료는 어떻게 발전하고 있을까?

유전성 주기성 발열 증후군의 확인에는 유전자 검사가 중심적인 역할을 하고 있습니다. MEFV, TNFRSF1A 및 기타 관련 유전자의 변이를 확인하기 위해 표적화 차세대 염기서열 분석(NGS) 패널과 엑솜 염기서열 분석이 3차 의료 기관에서 사용되고 있습니다. 바이오마커 연구, 특히 인터류킨-1(IL-1) 경로의 관여가 치료 결정의 지침이 되고 있습니다.

치료법은 아형에 따라 달라집니다. FMF에서는 코르히친이 표준 치료이며, PFAPA에서는 코르티코스테로이드가 자주 사용됩니다. IL-1(예: 아나킨라, 카나키누맙) 및 TNF-α를 표적으로 하는 생물학적 제제는 난치성 또는 유전적으로 확인된 증후군에 많이 사용되고 있습니다. 질병 조절 전략은 장기적인 장기 손상을 최소화하면서 발작의 빈도와 중증도를 감소시키는 것을 목표로 합니다.

임상 초점은 어디로 이동하고, 어떤 이해관계자가 연구에 투자하고 있는가?

진단과 치료의 주요 장소는 대학병원과 소아 류마티스 센터입니다. 북미와 유럽에서는 전국적인 희귀질환 등록 및 공동 연구 네트워크가 주기성 발열 증후군의 임상적, 유전적 특징을 규명하는 데 도움을 주고 있습니다. FMF가 더 많이 발생하는 중동 및 지중해 지역에서는 지역적 인식과 검진 프로그램이 강화되고 있습니다.

제약사들은 희귀질환치료제로 지정된 희귀증후군을 타겟으로 자가 염증성 질환의 생물학적 치료제에 투자하고 있습니다. 유전자 진단 기업들은 소아 자가 염증성 질환에 초점을 맞춘 패널을 개발하여 조기 개입을 가능하게 하고 있습니다. 환자 지원 단체는 전문의 치료와 생물학적 제제 치료에 대한 접근성을 개선하기 위해 임상의와 정책 입안자들의 인식을 개선하기 위해 노력하고 있습니다.

주기성 발열 증후군 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

주기성 발열 증후군 시장의 성장은 자가 염증성 질환에 대한 인식 개선, 유전자 검사에 대한 접근성 확대, 표적 생물학적 치료제의 사용 확대 등의 요인에 의해 주도될 것으로 예상됩니다. 진단 알고리즘의 개선, 소아과에서 시퀀싱을 광범위하게 적용함으로써 희귀한 발열성 증후군을 조기에 정확하게 식별할 수 있게 되었습니다.

희귀질환 치료제에 대한 규제 혜택과 IL-1 억제제, TNF 억제제의 적응증 확대가 바이오제약의 투자를 촉진하고 있습니다. 지속형 생물학적 제제 개발과 희귀질환 교육 프로그램을 통한 임상의의 인식 개선이 시장 성장을 더욱 촉진하고 있습니다. 환자 등록과 국경을 초월한 연구 이니셔티브가 성숙해짐에 따라 주기성 발열 증후군은 보다 체계적인 임상적 관심을 받고 있으며, 이는 이 전문 분야의 기술 혁신과 시장 확대를 촉진하고 있습니다.

부문

증후군(고면역글로불린혈증 D 증후군, 가족성 지중해열 증후군, TNF 수용체 관련 주기성 증후군, 크리오피린 관련 주기성 증후군, 기타 증후군), 치료(경구 항염증제, 비스테로이드성 항염증제, 항TNF 요법, 스타틴 치료, 기타 치료), 최종사용자(병원 최종사용자, 소매 약국 최종사용자)

조사 대상 기업 사례

  • AbbVie Inc.
  • AB2 Bio Ltd
  • Amgen Inc.
  • AstraZeneca plc
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Horizon Therapeutics(Amgen)
  • InnoCare Pharma
  • Kiniksa Pharmaceuticals
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sobi(Swedish Orphan Biovitrum)
  • Takeda Pharmaceutical Company

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.26

Global Periodic Fever Syndrome Market to Reach US$745.6 Million by 2030

The global market for Periodic Fever Syndrome estimated at US$618.8 Million in the year 2024, is expected to reach US$745.6 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. HyperimmunoGlobulinemia D syndrome, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$346.5 Million by the end of the analysis period. Growth in the Familial Mediterranean Fever Syndrome segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.6 Million While China is Forecast to Grow at 6.1% CAGR

The Periodic Fever Syndrome market in the U.S. is estimated at US$168.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$148.1 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Periodic Fever Syndrome Market - Key Trends & Drivers Summarized

What Characterizes Periodic Fever Syndromes and Why Are They Often Misdiagnosed?

Periodic fever syndromes are a group of rare, autoinflammatory disorders characterized by recurrent episodes of fever and systemic inflammation without infection. These syndromes, such as PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis), Familial Mediterranean Fever (FMF), and TRAPS (TNF Receptor-Associated Periodic Syndrome), typically present in childhood and are linked to mutations in genes regulating the innate immune system.

Misdiagnosis is common due to symptom overlap with infections or autoimmune diseases. As awareness grows, more accurate clinical recognition and genetic testing are helping clinicians differentiate between infectious, autoimmune, and autoinflammatory causes of recurrent fevers. Although rare, these syndromes have significant impacts on quality of life, school attendance, and caregiver burden, prompting early diagnosis and long-term care planning.

How Is Diagnosis and Treatment Progressing with Advancements in Genetics and Immunology?

Genetic testing plays a central role in confirming hereditary periodic fever syndromes. Targeted next-generation sequencing (NGS) panels and exome sequencing are increasingly used in tertiary centers to identify mutations in MEFV, TNFRSF1A, and other related genes. Biomarker studies, particularly interleukin-1 (IL-1) pathway involvement, are guiding treatment decisions.

Treatment approaches vary by subtype. Colchicine is the standard therapy for FMF, while corticosteroids are often used in PFAPA. Biologic therapies targeting IL-1 (e.g., anakinra, canakinumab) and TNF-alpha are increasingly used in refractory or genetically confirmed syndromes. Disease-modifying strategies aim to reduce attack frequency and severity while minimizing long-term organ damage.

Where Is the Clinical Focus Shifting and Which Stakeholders Are Investing in Research?

Academic hospitals and pediatric rheumatology centers are primary settings for diagnosis and care. In North America and Europe, national rare disease registries and collaborative research networks are supporting deeper clinical and genetic characterization of periodic fever syndromes. In the Middle East and Mediterranean regions, where FMF is more prevalent, regional awareness and screening programs are being strengthened.

Pharmaceutical companies are investing in biologic therapies for autoinflammatory diseases, targeting rare syndromes with orphan drug designations. Genetic diagnostics firms are developing panels focused on pediatric autoinflammatory conditions, enabling earlier intervention. Patient advocacy organizations are working to increase recognition among clinicians and policy makers to improve access to specialist care and biologic therapies.

Growth in the Periodic Fever Syndrome market is driven by several factors…

Growth in the periodic fever syndrome market is driven by factors such as increased recognition of autoinflammatory diseases, expanding access to genetic testing, and greater availability of targeted biologic therapies. Improved diagnostic algorithms, along with broader application of sequencing in pediatric medicine, are leading to earlier and more accurate identification of rare febrile syndromes.

Regulatory incentives for orphan drugs and expanded indications for IL-1 and TNF inhibitors are encouraging biopharma investment. Development of long-acting biologics and increased clinician awareness through rare disease education programs are further supporting market growth. As patient registries and cross-border research initiatives mature, periodic fever syndromes are receiving more structured clinical attention, driving innovation and market expansion in this specialized segment.

SCOPE OF STUDY:

The report analyzes the Periodic Fever Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Syndrome (HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome, Other Syndromes); Treatment (Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy, Statins Treatment, Other Treatments); End-Use (Hospitals End-Use, Retail Pharmacy End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • AB2 Bio Ltd
  • Amgen Inc.
  • AstraZeneca plc
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Horizon Therapeutics (Amgen)
  • InnoCare Pharma
  • Kiniksa Pharmaceuticals
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sobi (Swedish Orphan Biovitrum)
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Periodic Fever Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Autoinflammatory Disorders Spurs Demand for Targeted Treatments for Periodic Fever Syndromes
    • Increased Genetic Testing Capabilities Strengthen Early Identification and Classification of Hereditary Fever Disorders
    • Growth in Pediatric Rheumatology Awareness Throws the Spotlight on Underdiagnosed Recurrent Fever Conditions
    • Expansion of Biologic Therapies and IL-1 Inhibitors Supports Clinical Management of Resistant Cases
    • OEM Investment in Orphan Drug Development Encourages Pipeline Growth for Rare Autoinflammatory Indications
    • Advancements in Next-Generation Sequencing (NGS) Enhance Detection of Mutations in MEFV, TNFRSF1A, and Related Genes
    • Global Expansion of Autoinflammatory Disease Registries Improves Clinical Understanding and Therapeutic Strategy Development
    • Rising Adoption of Precision Medicine Supports Individualized Treatment Pathways in PFAPA and CAPS Patients
    • Pediatric Specialist Training and Referral Networks Promote Timely Diagnosis and Long-Term Disease Monitoring
    • Integration of Telehealth and Remote Monitoring Tools Facilitates Management of Flare Frequency and Response Tracking
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Periodic Fever Syndrome Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Periodic Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for HyperimmunoGlobulinemia D syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for HyperimmunoGlobulinemia D syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for HyperimmunoGlobulinemia D syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Familial Mediterranean Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Familial Mediterranean Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Familial Mediterranean Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for TNF Receptor-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for TNF Receptor-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for TNF Receptor-Associated Periodic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cryopyrin-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cryopyrin-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cryopyrin-Associated Periodic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Syndromes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Syndromes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Syndromes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oral Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Oral Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Anti-TNF Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Anti-TNF Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Anti-TNF Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Statins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Statins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Statins Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacy End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Retail Pharmacy End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Retail Pharmacy End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Periodic Fever Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Periodic Fever Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Periodic Fever Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Periodic Fever Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제